Cost-effectiveness Evaluation of Targeted Surgical and Endoscopic Therapies for Early Colorectal Adenocarcinoma Based on Biomarker Profiles

Overview

Journal JAMA Netw Open

Publisher American Medical Association

Specialty General Medicine

Date 2020 Mar 10

PMID 32150269

Citations 3

Authors

Se Ryeong Jang

Han Truong

Aaron Oh

Jin Choi

Angela C Tramontano

Monika Laszkowska

Chin Hur

Affiliations

Soon will be listed here.

Abstract

Importance: Colorectal cancer (CRC) is the second leading cause of cancer-related mortality in the United States. The prognosis for patients with CRC varies widely, but new prognostic biomarkers provide the opportunity to implement a more individualized approach to treatment selection.

Objective: To assess the cost-effectiveness of 3 therapeutic strategies, namely, endoscopic therapy (ET), laparoscopic colectomy (LC), and open colectomy (OC), for patients with T1 CRC with biomarker profiles that prognosticate varying levels of tumor progression in the US payer perspective.

Design, Setting, And Participants: In this economic evaluation study, a Markov model was developed for the cost-effectiveness analysis. Risks of all-cause mortality and recurrent cancer after ET, LC, or OC were estimated with a 35-year time horizon. Quality of life was based on EuroQoL 5 Dimensions scores reported in the published literature. Hospital and treatment costs reflected Medicare reimbursement rates. Deterministic and probabilistic sensitivity analyses were performed. Data from patients with T1 CRC and 6 biomarker profiles that included adenomatous polyposis coli (APC), TP53 and/or KRAS, or BRAFV600E were used as inputs for the model. Data analyses were conducted from February 27, 2019, to May 13, 2019.

Exposures: Endoscopic therapy, LC, and OC.

Main Outcomes And Measures: The primary outcomes were unadjusted life-years, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER) between competing treatment strategies.

Results: Endoscopic therapy had the highest QALYs and the lowest cost and was the dominant treatment strategy for T1 CRC with the following biomarker profiles: BRAFV600E, APC(1)/KRAS/TP53, APC(2) or APC(2)/KRAS or APC(2)/TP53, or APC(1) or APC(1)/KRAS or APC(1)/TP53. The QALYs gained ranged from 16.97 to 17.22, with costs between $68 902.75 and $77 784.53 in these subgroups. For the 2 more aggressive biomarker profiles with worse prognoses (APC(2)/KRAS/TP53 and APCwt [wild type]), LC was the most effective strategy (with 16.45 and 16.61 QALYs gained, respectively) but was not cost-effective. Laparoscopic colectomy cost $65 234.87 for APC(2)/KRAS/TP53 and $71 250.56 for APCwt, resulting in ICERs of $113 290 per QALY and $178 765 per QALY, respectively.

Conclusions And Relevance: This modeling analysis found that ET was the most effective strategy for patients with T1 CRC with less aggressive biomarker profiles. For patients with more aggressive profiles, LC was more effective but was costly, rendering ET the cost-effective option. This study highlights the potential utility of prognostic biomarkers in T1 CRC treatment selection.

Citing Articles

Bowel function, quality of life, and mental health of patients with high-grade intraepithelial neoplasia or T1 colorectal cancer after organ-preserving versus organ-resection surgeries: a cross-sectional study at a Chinese tertiary care center.

Cai Z, Yuan X, Li H, Feng X, Du C, Han K Surg Endosc. 2024; 38(10):5756-5768.

PMID: 39143332 DOI: 10.1007/s00464-024-11120-2.

Treatment for T1 colorectal cancers substratified by site and size: "horses for courses".

Shi K, Yang Z, Leng K Front Med (Lausanne). 2023; 10:1230844.

PMID: 37901402 PMC: 10602675. DOI: 10.3389/fmed.2023.1230844.

Cost-utility advantage of interventional endoscopy.

Sonnenberg A, Bauerfeind P, Bakis G Surg Endosc. 2022; 37(2):1031-1037.

PMID: 36097098 DOI: 10.1007/s00464-022-09599-8.

References

Neumann P, Cohen J, Weinstein M . Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014; 371(9):796-7. DOI: 10.1056/NEJMp1405158. View

Croke L . Colorectal Cancer Screening: ACS Updates Guideline for Adults with Average Risk. Am Fam Physician. 2019; 99(2):129-130. View

Nelson H, Sargent D, Wieand H, Fleshman J, Anvari M, Stryker S . A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 2004; 350(20):2050-9. DOI: 10.1056/NEJMoa032651. View

Liu Q, Luo D, Cai S, Li Q, Li X . P-TNM staging system for colon cancer: combination of P-stage and AJCC TNM staging system for improving prognostic prediction and clinical management. Cancer Manag Res. 2018; 10:2303-2314. PMC: 6074826. DOI: 10.2147/CMAR.S165188. View

Soerjomataram I, Thong M, Ezzati M, Lamont E, Nusselder W, van de Poll-Franse L . Most colorectal cancer survivors live a large proportion of their remaining life in good health. Cancer Causes Control. 2012; 23(9):1421-8. PMC: 3415614. DOI: 10.1007/s10552-012-0010-2. View

Yoda Y, Ikematsu H, Matsuda T, Yamaguchi Y, Hotta K, Kobayashi N . A large-scale multicenter study of long-term outcomes after endoscopic resection for submucosal invasive colorectal cancer. Endoscopy. 2013; 45(9):718-24. DOI: 10.1055/s-0033-1344234. View

Fearon E, Vogelstein B . A genetic model for colorectal tumorigenesis. Cell. 1990; 61(5):759-67. DOI: 10.1016/0092-8674(90)90186-i. View

Asayama N, Oka S, Tanaka S, Ninomiya Y, Tamaru Y, Shigita K . Long-term outcomes after treatment for T1 colorectal carcinoma. Int J Colorectal Dis. 2015; 31(3):571-8. DOI: 10.1007/s00384-015-2473-6. View

Sheetz K, Norton E, Regenbogen S, Dimick J . An Instrumental Variable Analysis Comparing Medicare Expenditures for Laparoscopic vs Open Colectomy. JAMA Surg. 2017; 152(10):921-929. PMC: 5710277. DOI: 10.1001/jamasurg.2017.1578. View

10.

Fearon E . Molecular genetics of colorectal cancer. Annu Rev Pathol. 2010; 6:479-507. DOI: 10.1146/annurev-pathol-011110-130235. View

11.

Binefa G, Rodriguez-Moranta F, Teule A, Medina-Hayas M . Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol. 2014; 20(22):6786-808. PMC: 4051918. DOI: 10.3748/wjg.v20.i22.6786. View

12.

Raju G, Lum P, Ross W, Thirumurthi S, Miller E, Lynch P . Outcome of EMR as an alternative to surgery in patients with complex colon polyps. Gastrointest Endosc. 2016; 84(2):315-25. PMC: 4949087. DOI: 10.1016/j.gie.2016.01.067. View

13.

Draganov P . Endoscopic Mucosal Resection Vs Endoscopic Submucosal Dissection for Colon Polyps. Gastroenterol Hepatol (N Y). 2018; 14(1):50-52. PMC: 5824597. View

14.

Jeong K, Cairns J . Systematic review of health state utility values for economic evaluation of colorectal cancer. Health Econ Rev. 2016; 6(1):36. PMC: 4991979. DOI: 10.1186/s13561-016-0115-5. View

15.

Puppa G, Sonzogni A, Colombari R, Pelosi G . TNM staging system of colorectal carcinoma: a critical appraisal of challenging issues. Arch Pathol Lab Med. 2010; 134(6):837-52. DOI: 10.5858/134.6.837. View

16.

Wilson T, Alexander D, Kind P . Measurement of health-related quality of life in the early follow-up of colon and rectal cancer. Dis Colon Rectum. 2006; 49(11):1692-702. DOI: 10.1007/s10350-006-0709-9. View

17.

Rex D, Hassan C, DeWitt J . Colorectal endoscopic submucosal dissection in the United States: Why do we hear so much about it and do so little of it?. Gastrointest Endosc. 2017; 85(3):554-558. DOI: 10.1016/j.gie.2016.09.015. View

18.

Kapidzic A, Korfage I, Van Dam L, van Roon A, Reijerink J, Zauber A . Quality of life in participants of a CRC screening program. Br J Cancer. 2012; 107(8):1295-301. PMC: 3494432. DOI: 10.1038/bjc.2012.386. View

19.

Chen Z, He X, Huang J, Zeng Y, Lian L, Wu X . Short-term outcomes between laparoscopy-assisted and open colorectomy for colorectal cancer in elderly patients: A case-matched control study. Mol Clin Oncol. 2015; 3(5):1155-1159. PMC: 4534871. DOI: 10.3892/mco.2015.585. View

20.

Paramasivam R, Angsuwatcharakon P, Soontornmanokul T, Rerknimitr R . Management of endoscopic complications, in particular perforation. Dig Endosc. 2013; 25 Suppl 2:132-6. DOI: 10.1111/den.12079. View